Clinical Trial Finder

Inclusion Criteria:

• - Patients must be older than 3 years and less than or equal to 25 years of age at the time of enrollment.

• - Patients with neurofibromatosis are eligible.

• - Histologic confirmation is not required for this if the patient has neurofibromatosis type 1 (NF-1) with MRI findings consistent with optic pathway glioma or JPA.

Any other tumors will need histological confirmation, either at the time of diagnosis or at the time of recurrence. The histological diagnosis includes World Health Organization (WHO) grade I JPA.

• - Patients must have measurable residual disease, defined as tumor that is measurable in two or three perpendicular diameters on MRI.

For a lesion to be considered measurable, it must be at least twice the slice thickness on MRI (i.e visible on more than one slice)

• - All patients must have a brain MRI with and without contrast (gadolinium) within 30 days prior to study enrollment.

All patients with history of spinal or leptomeningeal disease and those patients with symptoms suspicious of spinal disease, must have a spine MRI with contrast (gadolinium) performed within 30 days prior to study enrollment. Lumbar puncture is necessary if there is evidence of tumor dissemination on the MRI of spine.

• - Performance Level: Karnofsky > or equal to 50% for patients > 10 years of age or Lansky > or equal to 50 for patients < 10 years of age.

• - Patients must have recovered (to CTC v.

5.0 ≤ Grade 1 unless indicated below) from the acute toxic effects of all prior chemotherapy, immunotherapy prior to entering this study, with the exception of alopecia, weight changes and Grade I or II lymphopenia.

• - Must not have received myelosuppressive chemotherapy within 3 weeks of enrollment onto this study (6 weeks if prior nitrosourea) - At least 7 days must have elapsed since the completion of therapy with other biologic agents.

For other biologic agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur.

• - At least 3 half-lives of the antibody after the last dose of a monoclonal antibody.

Specifically for bevacizumab 36 days after the last dose.

• - At least 3 weeks from the last surgical resection, prior to start study drug.

• - At least 42 days after the completion of any type of immunotherapy, e.g. tumor vaccines.

• - Patients must have had their last fraction of cranial or craniospinal Radiation ≥ 24 months prior to study entry.

• - Patients who have received polyinosinic-polycytidylic acid-polylysine-carboxymethylcellulose (Poly-ICLC) are eligible for this trial if all acute Poly-ICLC -related toxicity has resolved.

• - Patients must not have received Pegylated interferon previously.

• - Must not have received growth factor within 2 weeks of entry into this study.

• - Patients who are receiving corticosteroids must be on a stable or decreasing dose for at least 1 week prior enrollment in the study.

• - Adequate organ, hematological, renal, and pulmonary function.

• - If history of depression or psychiatric illness, has to be well controlled with antidepressants and/or under psychiatrist/psychologist care.

Exclusion Criteria:

• - Patients who are receiving concurrent chemotherapy, or who are currently receiving other investigational chemotherapeutic agents or concurrently receiving radiation.

• - Patients with a known hypersensitivity to interferon-alpha.

• - Prior use of Pegylated interferon or interferon.

• - Less than 2 years since completion of radiation therapy.

• - Pregnant or breast-feeding females are excluded.

• - Patients with clinically significant unrelated systemic illness.

• - Dental braces or prosthesis that interferes with magnetic resonance (MR) imaging.

• - History of noncompliance to medical regimens.

• - Patients unwilling to or unable to comply with the protocol.

• - Patients with a positive history of Hepatitis B or Hepatitis C.

• - Male patient whose sexual partner(s) are women of childbearing potential who are not willing to use adequate contraception, during the study and for 8 weeks after the end of treatment.

• - Patients should not receive immunization with attenuated live vaccines within one week of study entry or during study period.

- Patient with diagnosis of Diffuse Intrinsic Pontine Glioma

Low grade gliomas are the most common pediatric central nervous system malignancies and can occur in different parts of the brain. Patients who undergo gross total resection, usually those with hemispheric tumors, have an excellent prognosis with surgical resection alone. Patients for whom gross total resection is not achievable have a significant risk of disease progression. Therefore, these patients benefit from adjuvant therapy. Multiple chemotherapy regimens have shown some efficacy in residual tumor, but more than 50% of patients experience recurrences. Radiation has been shown to be an effective therapy in the treatment of these tumors. Because of concerns regarding radiation toxicity especially in young children, and progression despite chemotherapy, novel approaches are needed. This protocol represents an attempt to measure the efficacy and safety of use of pegylated interferon for patients with recurrent, refractory Juvenile Pilocytic Astrocytomas (JPA) or optic pathway gliomas. It provides a different approach to the commonly used treatment modalities. The objectives of this study are to determine the response of children with chemotherapy-refractory progressive JPA or optic pathway gliomas (OPG) to weekly pegylated interferon alpha-2b. The secondary objectives include to better identify the toxicities of weekly pegylated interferon alpha-2b (PEG-Intron™) in pediatric patients with unresectable, refractory, recurrent JPAs or optic pathway gliomas, to evaluate various magnetic resonance imaging techniques for noninvasive monitoring of metabolic and biologic changes in the tumors and to evaluate the quality of life for patients with recurrent, refractory JPAs who receive therapy with pegylated interferon alpha-2b (PEG-Intron™). The primary end point is to determine the response rate. A two-stage design has been selected to evaluate the response rate. If the treatment demonstrates at least a 25% response rate, the researchers would consider it a promising regimen for further study. A response rate less than 5% is considered evidence of unpromising regimen. Seventeen evaluable pediatric patients with JPA or OPG will be accrued. If at least 3 responders are seen among the 17 patients, this will be considered evidence of a promising response rate for further evaluation.

Arms

Experimental: Pegylated interferon alpha-2b

Subjects will receive PEG-Intron based on their weight (1 mcg/kg/dose) once a week

Interventions

Drug: - Pegylated interferon alpha-2b

PEG-Intron 1mcg/kg/dose weekly through an injection under the skin on the same day each week